BMO Capital Initiates Coverage On Prime Medicine with Outperform Rating, Announces Price Target of $9
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsInitiationPrice Target
BMO Capital analyst David Lebowitz initiates coverage on Prime Medicine (NASDAQ:PRME) with a Outperform rating and announces Price Target of $9.
BMO Capital analyst David Lebowitz initiates coverage on Prime Medicine (NASDAQ:PRME) with a Outperform rating and announces Price Target of $9.